Introduction {#s1}
============

In vertebrates, the endothelial blood-brain barrier (BBB) is crucial for providing a permissive microenvironment for neuronal function. During developmental brain vascularization, blood vessels undergo Wnt/β-catenin signaling, driven by Wnt7a/7b that is required for angiogenesis as well as for BBB formation ([@bib11]; [@bib51]; [@bib28]). In the adult, the Wnt pathway remains instrumental to maintain BBB function in endothelial cells (ECs) of the central nervous system (CNS) ([@bib59]). Herein activation of β-catenin/TCF signaling can be induced by two flavors of the canonical Wnt pathway mediated by the ligands Wnt7a/7b and the non-Wnt-related norrin disease protein (Ndp), binding to the receptor complexes frizzled-4/Lrp5/6/Gpr124/Reck and frizzled-4/Lrp5/6/Tspan12, respectively ([@bib22]; [@bib5]; [@bib10]; [@bib46]; [@bib26]; [@bib58]; [@bib7]; [@bib55]; [@bib13]).

Although a strict control of the exchange between blood and the CNS tissue by the endothelial BBB is realized in most parts of the CNS, some areas of the brain and the ciliary body of the eye are exceptions to this rule, providing a physiologically highly relevant door to the CNS. The circumventricular organs (CVOs) are a number of small midline structures found in all vertebrate brains, located around the third and fourth ventricle. CVOs have a rich capillary plexus, which physiologically lacks BBB properties ([@bib18]; [@bib54]; [@bib27]; [@bib2]). These characteristics are regarded as important sites of communication between brain and blood. Based on their function, CVOs are commonly classified into secretory and sensory organs. The median eminence, the neurohypophysis (posterior pituitary, PP), the pineal gland (PI) and the subcommissural organ (SCO) belong to the secretory group. The vascular organ of the lamina terminalis (*organum vasculosum of the lamina terminalis*, OVLT), the subfornical organ (SFO) and the area postrema (AP) are considered as sensory organs ([@bib54]).

The leaky vessels of the CVOs evidently have different morphological and structural characteristics from those of typical BBB vessels, lacking a cellular organization as neuro-vascular unit (NVU), without distinctive astrocytic endfeet and ECs with numerous fenestrations and vesicles ([@bib37]). Interestingly, in previous reports neither the tight junction proteins claudin-5 (Cldn5), occludin (Ocln) and zonula occludens 1 (Tjp1/ZO-1) ([@bib40]; [@bib32]; [@bib42]; [@bib49]), nor the transporter proteins glucose transporter 1 (Glut-1) and transferrin receptor ([@bib42]; [@bib31]), showed a BBB-like staining in leaky CVO ECs. In line with these vascular features, Morita et al. showed that 10 kDa dextran accumulates in the perivascular space between the inner and outer basement membranes, whereas smaller tracers up to 3 kDa dextran diffuse into the parenchyma ([@bib37]). Not only the endothelium, but also the perivascular space in CVOs has specific properties, being enlarged and filled by collagen fibers, fibroblasts, astrocytic processes and axons ([@bib38]).

Beside the leaky vasculature of the CVOs, free diffusion of substances into the brain parenchyma is prohibited by tanycytes, specialized cells of the ependymal lining. Tanycytes contain long processes, unlike typical ependymal cells, which project to the parenchyma of the CVOs making contact to the fenestrated vascular wall of the CVOs ([@bib27]; [@bib2]; [@bib40]).

The detailed function of all CVOs has not intensely been explored in the past, but more recently, the SFO together with the OVLT, the median preoptic nucleus (MnPO) and the PP were identified as a functional circuit, regulating drinking behavior and water homeostasis of the organism ([@bib61]; [@bib43]; [@bib1]). The SFO is a tiny organ located underneath the fornix at the foramen of Monro, protruding into the third ventricle at the meeting point with the lateral ventricles. The dense vascular network in the SFO is similarly organized in different vertebrate species. It presents with heterogeneous vessel phenotypes and can therefore be divided into two zones. Whereas the outer shell contains more BBB expressing vessels, the majority within the ventromedial core is fenestrated with a wide perivascular space. In general, the vascular density is four to five times higher than in other brain regions with tortuous vessels, exhibiting a high blood volume and slow perfusion rate, thereby contributing to high permeability rates ([@bib49]; [@bib12]; [@bib16]; [@bib3]).

Although a cell type-specific expression analysis by single cell sequencing, as it has been performed for the brain parenchyma ([@bib56]), has not been conducted yet, neurons and astrocytes of sensory CVOs (SFO, OVLT and AP) were shown to express specific receptors and ion channels. Those permit them to detect several blood--derived molecules such as salts, hormones, lipids and toxins and convey this information to other parts of the brain, involved in controlling autonomic and peripheral functions ([@bib2]; [@bib49]). Evidence supports that 25--60% of CVO neurons respond to signals in the circulatory system and a single neuron may respond to multiple signals such as osmolarity and angiotensin II. Most sensory CVOs play a role in the control of blood pressure, fluid and sodium balance, cardiovascular regulation, feeding and energy homeostasis and immunomodulation ([@bib54]; [@bib2]; [@bib49]; [@bib38]; [@bib50]).

Given the fact that endothelial Wnt/β-catenin signaling is necessary for BBB development and maintenance, the question remains if the pathway is instrumental in the establishment of vascular heterogeneity in the CNS. Hence, we addressed the question if Wnt/β-catenin signaling is operational in CVO vessels during development and if local regulation of β-catenin signaling is involved in establishing a leaky vascular phenotype in CVOs. Finally, we asked if dominant activation of β-catenin in ECs can overwrite the leaky vessel fate thereby affecting CVO function.

Here we show by investigating CVOs during BAT-gal reporter mouse development that at any embryonic stage analyzed, starting from E13.5, when the first SFO primordium could be identified, to P21, no activation of β-catenin signaling in CVO vessels could be detected. Focusing on the SFO as a crucial CVO in the regulation of water homeostasis, we show that blood vessels in the caudal portion were mainly leaky evidenced by Plvap/Meca32 staining, whereas capillaries in the rostral portion of the organ were tighter. Interestingly, within the vessel continuity, individual ECs might be Plvap/Meca32^+^//Cldn5^-^ followed by a Plvap/Meca32^-^//Cldn5^+^ EC, suggesting a locally confined regulation of barrier properties. Dominant, genetic activation of β-catenin signaling (gain-of-function, GOF) in ECs resulted in tightening of CVO blood vessels, evidenced by the switch from a Plvap/Meca32^+^//Cldn5^-^ to a Plvap/Meca32^-^//Cldn5^+^ vascular phenotype. Vessel tightening was accompanied by a significant reduction in endothelial fenestrations, that likely contributed to the reduction of transcellular permeability evidenced by decreased tracer leakage. Interestingly, endothelial tightening did not coincide with the formation of astrocytic endfeet towards a BBB-like NVU. Finally, we observed augmented neuronal activity in the SFO under thirst conditions after sealing CVO vessels, supported by significantly increased neuronal c-fos staining in the SFO of GOF mice.

Results {#s2}
=======

Wnt/β-catenin signaling is not detectable in ECs of the developing CVOs {#s2-1}
-----------------------------------------------------------------------

As previously shown, BAT-gal mice report active Wnt/β-catenin in brain parenchymal vessels during embryonic and early postnatal brain vascularization ([Figure 1A](#fig1){ref-type="fig"}) ([@bib28]). So far, the developmental formation of CVOs and of the SFO in particular has not been investigated in mice. We made use of BAT-gal mice to monitor Wnt/β-catenin activity in CVO vessels at different time points of embryonic and postnatal mouse development, starting from E13.5 which was the first timepoint we could identify the primordial SFO, to P21 ([Figure 1B--E](#fig1){ref-type="fig"}, [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"} and [2](#fig1s2){ref-type="fig"}). In the SFO ([Figure 1B--E](#fig1){ref-type="fig"}) we could not detect an overlap of reporter gene-expression and CD31^+^ cells at any developmental stage analyzed. Instead, adjacent, non-endothelial cells in the ependymal lining as well as cells in the stroma of the organ showed active Wnt/β-catenin signaling, evidenced by nuclear β-galactosidase staining ([Figure 1B--E](#fig1){ref-type="fig"}). The latter observation suggested that Wnt growth factors are indeed available in the CVO region, but the canonical pathway was not activated in ECs.

![β-Catenin signaling is undetectable at different developmental stages in BAT-gal reporter mice.\
(**A**) Endothelial reporter gene expression, indicating β-catenin activity is detectable in cortical endothelial cells at E13.5 (arrowheads). (**B--E**) No β-catenin signaling could be detected in ECs at developmental stages E13.5, E17.5, P0 and P14 within the SFO. Arrows point to β-galactosidase positive nuclei. Scale bar: left (200 µm), middle (50 µm) and right column (20 µm).](elife-43818-fig1){#fig1}

Similarly, we did also not observe reporter gene-expressing ECs in the OVLT and in the PI ([Figure 1---figure supplements 1](#fig1s1){ref-type="fig"} and [2](#fig1s2){ref-type="fig"}), providing evidence for the interpretation that CVO endothelia generally show low or no Wnt/β-catenin activity.

We further wanted to address the question, whether the lack of Wnt pathway activation in CVO vessels is evolutionary conserved and analyzed the OVLT of adult Wnt pathway reporter zebrafish ([@bib21]). In all fish analyzed, OVLT vessels were largely devoid of GFP reporter gene expression, suggesting that Wnt/β-catenin activation is strongly reduced or absent in this CVO of the fish ([Figure 2](#fig2){ref-type="fig"}).

![Low Wnt/β-catenin signaling in the adult zebrafish OVLT.\
(**A**) Midline sagittal section of an adult *Tg(kdrl:ras-mCherry):Tg(7xTCF-Xia.Siam:EGFP)* zebrafish brain. The OVLT-containing area, anatomically-defined following [@bib21], is boxed in white. (**B**) Higher magnification view of (**A**). The dense and tortuous OVLT endothelium (red) exbibits low Wnt-reporter activity (green) compared to the surrounding vessels. (**C**) Same as (**B**) in another individual. Scale bars: (**A**) 500 μm, (**B**) and (**C**) 100 μm; Te, Telencephalon; Me, Mesencephalon; Di, Diencephalon; Ce, Cerebellum; Rh, Rhombencephalon.](elife-43818-fig2){#fig2}

In order to further characterize the vascular organization of the SFO, we analyzed adult wild type (WT) mice by confocal and light sheet microscopy.

Adult SFO vessels are highly heterogenous regarding their barrier properties {#s2-2}
----------------------------------------------------------------------------

As it has previously been proposed by Pócsai et al. that the SFO can be divided into a shell and a core region with different properties of astrocytes and extracellular matix (ECM), we intended to analyze the distribution of leaky and tight vessels within the SFO by staining for Plvap/Meca32 and Cldn5, respectively ([@bib45]). In order to visualize the organs, relevant for water homeostasis, we initially applied fluorescent microscopy on sagittal sections, showing that indeed, vessels in the SFO, OVLT and PP were Plvap/Meca32^+^, but also showed a considerable degree of intermingling with Cldn5^+^ ECs ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

In order to have a global view on vessel heterogeneity within the SFO, we prepared brains of WT C57Bl6 mice for whole mount staining ([Figure 3](#fig3){ref-type="fig"}). Light sheet microscopy analysis of whole mount preparations revealed that the majority of SFO vessels in the rostral portion, as well as of the shell were Plvap/Meca32^-^//Cldn5^+^, suggesting that these vessels possess BBB properties. Instead, vessels of the caudal SFO region were mainly Plvap/Meca32^+^//Cldn5^-^, providing evidence for their leaky phenotype ([Figure 3D](#fig3){ref-type="fig"}; [Video 1](#video1){ref-type="video"}). Higher magnification of the rostral part and the outer shell of the organ showed that some vessels exhibit a mosaic-like staining for Plvap/Meca32 and Cldn5 along their longitudinal extension ([Figure 3D](#fig3){ref-type="fig"}; [Video 1](#video1){ref-type="video"}). In order to visualize the alternating expression of leaky and tight vessel markers in more detail, we applied confocal microscopy on sagittal sections, revealing that neighboring cells may be positive either for Plvap/Meca32 or for Cldn5 ([Figure 3C](#fig3){ref-type="fig"}). However, some cells also showed a mixed identity, allowing the interpretation that there is a continuous transition from leaky-to-tight-to-leaky vessels in the SFO.

![Heterogeneous barrier phenotype in vessels of the adult wild type subfornical organ (SFO).\
(**A**) Sagittal scheme of all circumventricular organs (CVOs) (left overview), the SFO in detail (middle sagittal, right coronal) provide an orientation. (**B**) Heterogenous barrier phenotype in coronal fluorescence images, (**C**) sagittal confocal projections of the rostral SFO tip and (**D**) light sheet projections of whole mount SFO samples with leaky MECA32^+^ and tight Cldn5^+^ vessels. Scale bars: (**B**) 100 µm, (**D**) first picture 50 µm and following 20 µm. SFO, Subfornical organ; OVLT, organum vasculosum of lamina terminalis; ME, median eminence; PP, posterior pituitary; SCO, subcommisural organ; PI, pinal organ; AP, area postrema; SV, septal veins; V-III, third ventricle; CP, choroid plexus; CC, corpus callosum; SF, septofimbrial nucleus; TL, tomato lectin; VR, volume rendering.](elife-43818-fig3){#fig3}

###### Heterogeneous barrier phenotype in vessels of the adult wild type subfornical organ (SFO).

Video of a cleared whole mount preparation of the SFO and neighboring tissue, stained for Cldn5 (red), Meca32/Plvap (green) and i.v.-injected tomato-lectin-Alexa649 (blue) as a general vessel marker. Volume rendering demarcates SFO vessels.

10.7554/eLife.43818.009

As we observed an alternating barrier phenotype in the SFO vasculature, we addressed the questions if dominant activation of β-catenin signaling in ECs may lead to vessel tightening of CVO vessels, particularly in the SFO.

Dominant activation of β-catenin in ECs seals SFO vessels {#s2-3}
---------------------------------------------------------

To dominantly activate the Wnt/β-catenin pathway in ECs, Cdh5(PAC)-CreERT2:Ctnnb1^E×3fl/fl^ (GOF) double-transgenic mice were induced with tamoxifen (TAM) either directly after birth for three (50 µg/day, P1-P3, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}) or in the adult for five (500 µg/day, 8--10 week-old mice, [Figure 4](#fig4){ref-type="fig"}) consecutive days.

![Endothelial-specific β-catenin GOF tightens the vasculature of the subfornical organ (SFO).\
(**A**) Mouse model and (**B**) schedule of endothelial-specific β-catenin GOF induction by tamoxifen (TAM) . Coronal view of the subfornical organ (SFO) (**C**) 16 , (**D**) 19 and (**E**) 26 days after the first TAM injection. (**F**) Quantification for Cldn5 and (**G**) Meca32-covered vessel area within the SFO (n = 3 per group). (**H**) Relative mRNA expression of SFO whole mount tissue (n = 1 of pooled samples (Cre^- ^= 18 mice, Cre^+ ^= 17 mice)). Scale bars: (**C--E**) 100 µm; error bars show ±SEM.\
10.7554/eLife.43818.016Figure 4---source data 1.Quantification of endodthelial-specific β-catenin GOF-mediated vessel tightening in the vasculature of the subfornical organ (SFO) of Cdh5(PAC)-CreERT2:Ctnnb1Ex3fl/wt mice.\
10.7554/eLife.43818.017Figure 4---source data 2.Quantification of Meca32 and Cldn5 mRNA expression by qRT-PCR in the vasculature of the subfornical organ (SFO) of Cdh5(PAC)-CreERT2:Ctnnb1Ex3fl/wt mice.](elife-43818-fig4){#fig4}

We initially determined recombination efficiency in the brain by analyzing Cdh5(PAC)-CreERT2:mTmG reporter mice ([@bib57][@bib41]), suggesting that VE-cadherin efficiently drives endothelial recombination in brain vessels ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

β-Catenin GOF pups were analyzed at P6 and P14 and compared to respective controls. At both timepoints analyzed (P6 and P14), control vessels exhibited high levels of Plvap/Meca32 and low levels of Cldn5 immunolabeling ([Figure 4---figure supplement 1A,B](#fig4s1){ref-type="fig"}). Interestingly, endothelial-specific β-catenin GOF reverted this phenotype, resulting in significantly decreased Plvap/Meca32 immunoreactivity, whereas Cldn5 expression was markedly increased in these vessels without any changes in VE-cadherin immunolabeling at P6 ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). In the adult, the same antagonistic regulation of Plvap/Meca32 and Cldn5 by β-catenin GOF was observed as in postnatal stages ([Figure 4B--D](#fig4){ref-type="fig"}; quantification 4E, F).

When analyzing different timepoints after TAM induction of adult GOF mice for the expression of Plvap/Meca32 and Cldn5, we observed that activation of β-catenin signaling significantly suppressed Plvap/Meca32 and induced Cldn5 already by day 16 ([Figure 4E,F](#fig4){ref-type="fig"}). Maximal Cldn5 induction was observed after 26 days, being significantly higher than at day 19 after the first TAM injection ([Figure 4E](#fig4){ref-type="fig"}). Analysis of pooled mRNA from 17 whole SFOs from GOF or control mice, revealed that Plvap/Meca32 was indeed down-regulated in the GOF condition on the mRNA level, whereas Cldn5 did not show an obvious regulation. This suggested that transformation of the leaky into a tight vessel phenotype in the SFO by β-catenin GOF requires around 26 days after induction of recombination.

To understand if beside Cldn5 also other tight junction components are regulated upon β-catenin activation in SFO endothelial cells, we stained for occludin (Ocln) and zonula occludens 1 (ZO-1). Analyzing the junctional localization of Ocln normalized to the vessel length in the SFO, we observed only a punctuated staining of Ocln at endothelial cell-cell junctions of controls as previously described by Morita et al. ([@bib38]). In vessels of GOF mice we noted a significant increase in line-like junctional Ocln staining compared to controls ([Figure 5A,B](#fig5){ref-type="fig"}; quantification [Figure 5C](#fig5){ref-type="fig"}). Further analysis of mRNA of pooled SFO samples from GOF or control mice, revealed that Ocln, like Cldn5, did not show an obvious regulation in the GOF condition ([Figure 5D](#fig5){ref-type="fig"}). As opposed to Cldn5 and Ocln, ZO-1 showed only a moderately increased localization at cell-cell junctions in SFO vessels of GOF mice ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Specifically, ZO-1 was consistently present at inter-endothelial junctions of the SFO in the control condition.

![Endothelial-specific β-catenin GOF leads to increased occludin localization at cell-cell junctions in the vasculature of the subfornical organ (SFO).\
(**A**) Coronal view of the subfornical organ (SFO) 26 days after the first TAM injection; dashed line demarcates the SFO. (**B**) Higher magnification of an SFO vessel indicated by the rectangular inset in A, white dashed lines show Meca32^+^, green dashed lines show Meca32 vessels, arrows indicate junctional Ocln staining. (**C**) Quantification for Ocln junctional length normalized to the vessel area within the SFO (n = 3 per group). (**D**) Relative mRNA expression of SFO whole mount tissue (n = 1 of pooled samples (Cre^-^=18 mice, Cre^+^=17 mice)) . Scale bars: (**A**) 50 µm, (**B**) 10 µm; error bars show ±SEM.\
10.7554/eLife.43818.020Figure 5---source data 1.Quantification of occludin localization at cell-cell junctions in the vasculature of the subfornical organ (SFO) in Cdh5(PAC)-CreERT2:Ctnnb1Ex3fl/wt mice.\
10.7554/eLife.43818.021Figure 5---source data 2.Quantification of occludin mRNA expressionby qRT-PCR in the vasculature of the subfornical organ (SFO) in Cdh5(PAC)-CreERT2:Ctnnb1Ex3fl/wt mice.](elife-43818-fig5){#fig5}

As the upregulation of the junctional proteins Cldn5 and Ocln support the interpretation of an SFO vessel tightening in GOF mice, it remained to be clarified if vessel permeability is indeed affected by dominant β-catenin activation in ECs. To this end, GOF and control mice were intravenously injected with FITC-bovine serum albumin (FITC-BSA) (\~68 kDa), and examined after 1.5 hrs of circulation. Analysis of FITC-BSA leakage normalized to vessel area revealed a significant reduction of extravasation in SFO vessels of the GOF versus control mice ([Figure 6](#fig6){ref-type="fig"}). Specifically, the leaky vessels in the controls showed pronounced FITC-BSA distribution in the circumference of vessels indicated by a prominent cloudy FITC signal in the entire SFO, whereas in the GOF condition the tracer remained confined to the vessel lumen ([Figure 6C](#fig6){ref-type="fig"}).

![Reduction of vascular permeability by endothelial specific β-catenin gain-of-function (GOF).\
(**A**) Overview and (**C**) high magnification shows leakage of FITC labelled albumin within the SFO of Cre^-^ and Cre^+^ mice. Dashed lines indicate SFO (**A**) or vessel outline (**C**). (**B**) Quantification of FITC-positive SFO area normalized to the vessel area (Cre^-^ = 4 mice, Cre^+^ = 3 mice). Scale bars: (**A**) 100 µm; (**C**) 50 µm; error bars show ±SEM.\
10.7554/eLife.43818.023Figure 6---source data 1.Quantification of FITC-BSA extravasation in the vasculature of the subfornical organ (SFO) in Cdh5(PAC)-CreERT2:Ctnnb1Ex3fl/wt mice.](elife-43818-fig6){#fig6}

To strengthen the observation of SFO vessel tightening, we performed β-catenin GOF experiments also with the Pdgfb-iCreERT2 mouse driver line ([@bib8]), resulting in comparable regulation of Plvap/Meca32 and Cldn5 ([Figure 4---figure supplement 3A,B](#fig4s3){ref-type="fig"}). Activation of the Wnt/β-catenin pathway was supported by significantly increased nuclear Sox17 localization that was reported to be a downstream target of Wnt/β-catenin and to be upstream of Notch ([@bib9]; [@bib60]) ([Figure 4---figure supplement 3C,D](#fig4s3){ref-type="fig"}).

Given the increase in Cldn5 expression in SFO vessels, we addressed if the endothelial tightening may also have an effect on the organization of the NVU within the core region of the SFO, in which no astrocytic endfeet are formed around vessels. Therefore, we stained GOF and control SFOs for the astrocytic endfeet markers aquaporin-4 (Aqp4), α-dystroglycan (αDag) and Kir4.1 ([Figure 7---figure supplements 1](#fig7s1){ref-type="fig"} and [2](#fig7s2){ref-type="fig"}), as well as the ECM markers laminin α 2 (Lama2) and collagen IV (ColIV) ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). All markers revealed the expected polarized distribution around BBB vessels in the striatum, nicely confirming staining specificity ([Figure 7---figure supplements 1A](#fig7s1){ref-type="fig"} and [2A,D](#fig7s2){ref-type="fig"}).

As previously shown for astrocytic endfeet proteins ([@bib45]), leaky SFO vessels did not exhibit pronounced staining of the polarity markers αDag and Kir4.1 ([Figure 7---figure supplements 1B,C and](#fig7s1){ref-type="fig"} and [2B,C](#fig7s2){ref-type="fig"}). Moreover, none of these stainings were found to be affected by the GOF conditions, meaning that no distinct staining of vascular endfeet could be observed. Specifically, Aqp4 and αDag showed only a weak, unpolarized localization around vessels in GOF and controls, whereas the sodium channel Kir4.1 was mainly expressed by cells morphologically resembling tanycytes in the SFO ([Figure 7---figure supplements 1B,C and](#fig7s1){ref-type="fig"} and [2B,C](#fig7s2){ref-type="fig"}). The ECM components Lama2 and ColIV, revealed that in GOF and in control vessels of the SFO a vascular and an astrocytic basal lamina was present with no obvious differences in structure and distribution between conditions ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}).

In order to further characterize the blood vessels in the SFO of β-catenin GOF mice, we employed electron microscopy to visualize their subcellular phenotype. As expected, the vessels in control SFOs showed the typical large and lacuna-like structure with an extensive ECM circumference ([Figure 7A--C](#fig7){ref-type="fig"}). Moreover, fenestrations were frequently observed in the control condition, a morphological feature that is consistent with a high Plvap/Meca32 expression and a permeable phenotype ([Figure 7C](#fig7){ref-type="fig"}; quantification [Figure 7D](#fig7){ref-type="fig"}). Although the vessel morphology did not show major differences regarding vessel perimeter and structure, the vessels of the GOF mice appeared to have a more compact ECM deposition in their circumference ([Figure 7A--C](#fig7){ref-type="fig"}). Endothelial vesicles did not show obvious alterations between GOF and controls (data not shown). Instead, the junctional area of GOF vessels was considerably more elaborate compared to the controls, which exhibited typical blunt-ending connections ([Figure 7C](#fig7){ref-type="fig"}). Additionally, fenestrations were significantly reduced in GOF mice, being in line with the reduction of Plvap/Meca32 immunostaining ([Figure 4E](#fig4){ref-type="fig"}; quantification [Figure 4G](#fig4){ref-type="fig"}) and further suggesting that β-catenin GOF in ECs is crucial for the suppression of a leaky vessel phenotype.

![Tightening of vessels in the subfornical organ (SFO) on cellular level.\
(**A**) Semithin sections of SFO of endothelial-specific β-catenin GOF (Cre^+^) and controls (Cre^-^). Electron microscopic picture of Cre^-^ (**B**), (**C**), left column) and Cre^+^ (**B**), (**C**), right column). Black arrow heads indicate fenestrations, with arrows endothelial junctions, asterisks show vesicles. AC, astrocyte; EC, endothelial cell; L, lumen; PC, pericyte. (**D**) Number of fenestrations are quantified in three vessel sections per animal (n = 4). Error bars show ±SEM.\
10.7554/eLife.43818.027Figure 7---source data 1.Quantification of endothelial fenestrations in the vasculature of the subfornical organ (SFO) in Cdh5(PAC)-CreERT2:Ctnnb1Ex3fl/wt mice.](elife-43818-fig7){#fig7}

Upon the observation that dominant endothelial activation of Wnt/β-catenin signaling established barrier properties in SFO vessel, we wanted to elucidate if the tightening of SFO vessels affects neuronal function in this organ.

Endothelial β-catenin GOF results in augmented neuronal activity in the SFO of water-restricted mice {#s2-4}
----------------------------------------------------------------------------------------------------

In order to understand if dominant activation of β-catenin signaling in ECs of the SFO may influence neuronal activity in the context of water homeostasis and drinking behavior, we induced thirst in adult mice and analyzed neuronal activity. To this end, WT mice were either kept for 72 hrs under water restriction ([Figure 8A](#fig8){ref-type="fig"}) or were intraperitoneally injected with a hyperosmolar NaCl (3 M) solution 50 min prior to sample collection ([Figure 8B](#fig8){ref-type="fig"}) and subsequent assessment of neuronal activation by c-fos staining in the SFO ([Figure 8C,D](#fig8){ref-type="fig"}). The Nissl staining of the so-called Nissl flounders nicely documents the neuronal identity of the c-fos^+^ cells ([Figure 8](#fig8){ref-type="fig"}). As opposed to the general nuclear staining by the fluorescent Nissl stain, the flounders are specific for neurons only.

![Neuronal activation via thirst induction in wild type animals.\
(**A**) Schedule of water restriction paradigm. Small blue droplets represent a restricted amount of water in a 24 hrs cycle according to the bodyweight (BW). (**C**) c-fos activation in the SFO of mice with water *ad libitum* and animals restricted for 72 hrs. (**E**) quantification of c-fos positive/DAPI nuclei in the SFO (n = 3). (**B**) Experimental setting of hyperosmolar sodium chloride injection. Animals get either isotonic (0.15 M) or 3 M sodium chloride intraperitoneally injection (150 µl/20 g mouse). c-fos analysis 50 min after NaCl injection (**D**) and quantification (**F**) (n = 6). Dashed lines indicate Nissl flounders confirming neuronal idendity of c-fos^+^ (**G**) and c-fos^-^ (**H**) cells. Scale bars: (**C**), (**D**) 50 µm, (**G**), (**H**) 2 µm; error bars show ±SEM.\
10.7554/eLife.43818.031Figure 8---source data 1.Quantification of dose dependent neuronal activity in the subfornical organ (SFO) upon hyper-osmolar sodium chloride injection.](elife-43818-fig8){#fig8}

Both thirst-inducing paradigms lead to a significant increase in c-fos^+^ neurons in the SFO of WT mice ([Figure 8](#fig8){ref-type="fig"}). We could also show a dose-dependent c-fos activation in thirst induction by hyperosmolar NaCl, comparing 2 M and 3 M solutions ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). Given that water restriction is a more physiological setting which reflects the restricted availability of resources in nature, we made use of this paradigm to investigate the influence of β-catenin GOF on neuronal activity in the SFO.

Under control conditions, in which mice received water *ad libitum*, we could not detect any genotype-specific differences in c-fos^+^ nuclei in the SFO between control and GOF animals (data not shown). β-Catenin GOF and control mice were subjected to water restriction 26 days after induction by TAM ([Figure 9A](#fig9){ref-type="fig"}). In case of water restriction for 72 hrs ([Figure 9A](#fig9){ref-type="fig"}) a slight, but stable weight loss was induced in GOF and control mice in the same manner ([Figure 9B](#fig9){ref-type="fig"}). Analysis of c-fos activation revealed a significantly higher neuronal activity in the SFO of GOF mice ([Figure 9D](#fig9){ref-type="fig"}). This suggests that tightening SFO blood vessels may have physiological consequences for the water homeostasis in mice.

![Vascular tightening effects increased neuronal activity in the subfornical organ (SFO) under thirst conditions.\
(**A**) Experimental setup of water restriction in β-catenin GOF and control mice after tamoxifen (TAM) injection. (**B**) Monitoring of BW for GOF and control mice under water restriction. (**D**) c-fos activation (dashed lines indicate the SFO) and (**C**) quantification of c-fos positive/DAPI nuclei in the SFO (n(Cre^-^) = 9, n(Cre^+^) = 8). Scale bars show 50 µm; error bars show ±SEM.\
10.7554/eLife.43818.033Figure 9---source data 1.Quantification of neuronal activity in the subfornical organ (SFO) under thirst conditions in Cdh5(PAC)-CreERT2:Ctnnb1Ex3fl/wt mice.](elife-43818-fig9){#fig9}

Discussion {#s3}
==========

The present study deals with the regulation of the leaky vascular phenotype in the CVOs and in the SFO in particular. Specifically, we addressed the questions, a) if the Wnt/β-catenin pathway is operational in ECs of CVOs during murine development and in the adult mouse and zebrafish, b) if endothelial-specific, dominant activation of β-catenin transcription could convert the leaky vascular phenotype in CVOs and c) if the latter may have an effect on CVO function.

The principle findings of this study are: 1) Wnt/β-catenin signaling is undetectable in CVO vessels during BAT-gal reporter mouse development; 2) similarly, β-catenin-mediated transcription is strongly reduced in the adult zebrafish OVLT; 3) SFO vessels are heterogenous regarding the expression of Plvap/Meca32 and Cldn5; 4) upon genetic β-catenin GOF in ECs, leaky SFO vessels are partially converted into tight vessels; 5) functional conversion of SFO vessel towards a BBB-like identity affects neuronal activity in the SFO.

Wnt/β-catenin is crucial for brain vascularization and BBB development, by regulating endothelial sprouting as well as by promoting a BBB expression profile in ECs, respectively ([@bib55]; [@bib28]; [@bib11]; [@bib51]; [@bib59]). CVOs are well known, but poorly investigated, structures in the midline of vertebrate brains, conferring neurosensory and/or neurosecretory function. Because of this physiological function, CVO blood vessels were described for a long time to lack BBB characteristics, a feature that is considered to be important for allowing neurons to 'sense' salts, hormones, lipids and toxic compounds in the blood ([@bib49]; [@bib23]). Indeed, it has been shown that neurons send axons into the extended perivascular space, which is in line with their sensory function ([@bib38]). The peculiar, leaky specialization of the CVO vascular system is well documented, showing tortuous and fenestrated vessels with poorly developed inter-endothelial junctions ([@bib35]). However, how this specialization is induced on a molecular level during development and how it is maintained is currently not well understood. Vascular endothelial growth factor (VEGF) is the best described inducing factor for endothelial fenestrations and is reported to be expressed in sensory CVOs as well as in other tissues that physiologically require endothelial fenestrations, such as the choroid and the ciliary body of the eye ([@bib17]; [@bib15]; [@bib24]).

As the Wnt/β-catenin pathway is considered a master switch for barriergenesis, we hypothesized that β-catenin transcription is not operational during CVO vascularization. The data provided here support this interpretation, as in BAT-gal reporter mice, from the initial identification of the SFO primordium at E13.5, none of the investigated developmental stages revealed a single β-galactosidase-positive vessel within the CVOs ([Figure 1](#fig1){ref-type="fig"}; [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"} and [2](#fig1s2){ref-type="fig"}). Although this finding may formally not exclude low level activation of the pathway in ECs, the observation that neighboring, non-endothelial cells in the CVOs, do show Wnt pathway activation, supports the interpretation of low or absent Wnt/β-catenin signaling in CVO ECs. Specifically, we observed that the ependymal cells covering the SFO as well as stromal cells in the core of the organ show Wnt/β-catenin pathway activation ([Figure 1](#fig1){ref-type="fig"}). Quantitative RT-PCR revealed also expression of Wnt3a, Wnt7 as well as Fzd4 in the SFO, suggesting that at least the BBB-inducing machinery is expressed (data not shown). As also in the adult, β-catenin-mediated transcription in ECs is required to maintain BBB function, the absence of reporter activity in mouse (data not shown) or zebrafish models presented in this study, further underlines that Wnt is evidently not operational in CVO vessels. This may support the hypothesis that Wnt/β-catenin signaling is actively suppressed in the SFO and likely also in other CVOs that have fenestrated vessels. So far, no conclusive data are available demonstrating Wnt pathway inhibitors in the CVOs, however, it has been shown that expression of the soluble frizzled receptor protein 1 (Sfrp1) is about 30 times higher in the rat choroid plexus (CP), that also lacks BBB vessels, compared to the striatum and parietal cortex ([@bib4]). Nevertheless, a detailed analysis of the CVOs regarding cell type-specific expression profiles has not been published yet.

Still, it has to be noted that vessels in the SFO, OVLT and PP are heterogenous regarding the expression of Plvap/Meca32 and Cldn5 ([Figure 3](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Similarly, differentially tight vessels were also shown in other CVOs ([@bib38]). This raises the question if in the CVOs, unlike in the brain parenchyma a '...gradual phenotypic change (zonation) along the arteriovenous axis...' is realized ([@bib56]), or if alternating endothelial differentiation might be established by factors yet to be discovered.

The present findings may suggest that, at least to some degree, vascular phenotypes in the SFO are locally regulated, which would be in line with their role providing local access for neurons to the blood milieu. If vessel differentiation might also be dynamically regulated to control water homeostasis in a circadian rhythm ([@bib19]), is currently unknown and subject to ongoing investigation. In this regard it is interesting to note however, that Cldn5 and Ocln mRNA were not significantly upregulated when analyzed in whole mount dissected SFOs from GOF mice ([Figures 4H](#fig4){ref-type="fig"} and [5D](#fig5){ref-type="fig"}). This might be due to several reasons, such as signal masking by other vessels in the whole mount preparations. Alternatively, this finding might support the interpretation that Cldn5 and Ocln are not transcriptionally regulated by β-catenin, but rather regulated on a post-transcriptional level. Interestingly, there is still some controversy about Cldn5 regulation by Wnt/β-catenin, as it has been shown by Taddei et al. that β-catenin cooperates with FOXO1 to suppress Cldn5 at the promotor level under pro-angiogenic conditions ([@bib52]). On the other hand, it has been shown that Sox18, a member of the SOX family of high-mobility group box transcription factors, is instrumental in activating Cldn5 transcription, contributing to endothelial barrier formation ([@bib14]). Given the high redundancy of SoxF genes (Sox7, 17, 18) ([@bib60]), it might be feasible that Sox17, that we report here to be upregulated in SFO vessels of β-catenin GOF mice ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), mediates Cldn5 regulation.

Although the regulation of Cldn5 on the promotor level and the role of β-catenin herein requires additional investigation, the tightening of SFO vessels by Cldn5 protein upregulation in β-catenin GOF mice is consistent with previous reports in other regions of the brain ([@bib59]). Interestingly, in the SFO of GOF mice, we also observed a significantly augmented junctional localization of Ocln, which is in line with the endothelial tightening, but, like for Cldn5, at which molecular level the Ocln regulation occurs remains to be clarified. Moreover, the adherens and tight junction-associated protein ZO-1 qualitatively showed a slight increase in junctional continuity in the GOF condition, which fits with the overall formation of more elaborate junctional complexes between ECs. The fact that ZO-1 exhibits also junctional staining in the controls ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), is consistent with its role in VE-cadherin-based adherens junctions, which are also formed by SFO vessels ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}) ([@bib53]).

Beside the mere upregulation of Cldn5 and Ocln, endothelial β-catenin GOF resulted in the abolishment of fenestrations and strengthened inter-endothelial junctions. These findings are well in line with a reduction in VEGF signaling in glioma ECs upon Wnt/β-catenin activation via the downregulation of VEGF receptor 2 (VEGFR2, flk-1) and upregulation of VEGFR1 ([@bib47]). This suggests that also upon β-catenin GOF in CVO vessels the responsiveness of ECs for VEGF could be reduced, leading to regression of fenestrations. Interestingly, the structural components of the NVU such as astrocytic endfeet and ECM, additional crucial BBB features, were not observed to be changed by the GOF condition ([Figure 7---figure supplements 1](#fig7s1){ref-type="fig"} and [2](#fig7s2){ref-type="fig"}). Also, the vessel coverage by pericytes showed no major changes in the SFO comparing GOF and controls (data not shown). If the perivascular fibroblasts, recently described by Vanlandewijck et al. ([@bib56]), are present at SFO vessels and if yes, whether they are affected by β-catenin GOF in ECs has to be determined in future investigations. Hence, to form the NVU structure might require additional cues and/or prolonged time to form, although the latter explanation might not be as likely as the first, given that even after sixty days after TAM injection the control-like phenotype persisted (data not shown). These findings support the conclusion that tightening the ECs in the SFO via β-catenin GOF does not lead to pronounced structural alterations at the NVU. As the leaky vessels of the SFO core are surrounded by a prominent perivascular space, which is considered to be important for the communication of neuronal axons with the blood milieu, it might be therapeutically beneficial that the NVU is not affected by the dominant activation of endothelial β-catenin.

One of the main questions investigated in the present work is how the vasculature in the sensory CVOs like the SFO functionally cooperates with the neurons and other stromal cells to achieve proper physiological regulation of fundamental body parameters like water homeostasis. So far, the vasculature has drawn little attention in this respect, even though considerable progress has recently been made to unravel the regulation of drinking behavior by the SFO, OVLT and the PP ([@bib19]; [@bib34]; [@bib43]; [@bib61]; [@bib1]). Specifically, it was shown for the SFO that two distinct populations of neurons expressing ETV-1 and Vgat mediate thirst-ON and thirst-OFF signals, respectively ([@bib43]). Here we provide evidence for an essential role of endothelial barrier function in neuronal activation in water restricted mice, as neuronal c-fos reactivity was increased in water-deprived GOF animals ([Figure 9](#fig9){ref-type="fig"}). How this finding relates to the drinking behavior and to the activity of excitatory and inhibitory neuronal signals to and from the median preoptic nucleus (MnPO), which was shown to host the behavioral output neurons ([@bib1]), is beyond the scope of this study and is subject to future work. Moreover, it remains to be clarified if the increased c-fos signal in the SFO of GOF mice is directly caused by the tightened vessel phenotype, or indirectly affected by an altered angiocrine profile of the tightened endothelium, potentially leading to altered drinking behavior. Preliminary analysis of primary mouse brain microvascular ECs (MBMECs) treated with Wnt3a revealed no regulation of VEGF that was previously described to be neuroactive (data not shown) ([@bib29]).

Although own preliminary experiments aiming to pharmacologically tighten CVO vessels with a systemically administered Wnt/β-catenin activator did not result in SFO vessel tightening (data not shown), this might be a potential way to therapeutically modulate water intake. Interestingly, patients that chronically receive LiCl, an FDA-approved drug for bipolar disorders and a potent Wnt/β-catenin activator, frequently develop polyuria that is linked to altered anti-diuretic hormone (ADH; vasopressin) function, which is released by the PP. Moreover, many patients develop polydipsia and urinate more frequently ([@bib30]). Hence in-depth investigation of the pharmacologic modulation of SFO vessel permeability is required. Although the detailed mechanisms underlying the neuro-vascular coupling in the CVOs have to be investigated in more detail, in light of the present work however, the CVO vasculature likely participates actively in controlling water homeostasis.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\               Designation                                           Source or reference                                                                       Identifiers                                                                   Additional\
  (species)\                                                                                                                                                                                                                                                information
  or resource                                                                                                                                                                                                                                               
  --------------------------- ----------------------------------------------------- ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- ----------------
  Strain, strainbackground\   Wild-type mice                                        ENVIGO, The Netherlands                                                                   C57BL/6J                                                                      
  (*Mus musculus*)                                                                                                                                                                                                                                          

  Strain, strainbackground\   Cdh5-cre mice                                         Ralf H. Adams,\                                                                           Cdh5(PAC)-CreERT2                                                             
  (*Mus musculus*)                                                                  Max-Planck-Institute for Molecular Biomedicine, Münster, Germany                                                                                                        

  Strain, strainbackground\   Pdgfb-cre mice                                        Marcus Fruttiger (University College London, London, UK                                   PDGFB-iCreERT2                                                                
  (*Mus musculus*)                                                                                                                                                                                                                                          

  Strain, strainbackground\   β-Catenin exon3-floxed mice                           M. Mark Taketo, Kyoto University, Japan                                                   Ctnnb1^Ex3fl/fl^                                                              
  (*Mus musculus*)                                                                                                                                                                                                                                          

  Strain, strainbackground\   Wnt/β-catenin reporter mice                           Stefano Piccolo (University of Padua, Padova,Italy)                                       B6.Cg-Tg(BAT-lacZ)3Picc/J                                                     
  (*Mus musculus*)                                                                                                                                                                                                                                          

  Strain, strainbackground\   Cre-reporter mice                                     Liqun Luo, Stanford University                                                            STOCK *Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo^*/J                          
  (*Mus musculus*)                                                                                                                                                                                                                                          

  Strain, strainbackground\   Vessel reporter fish                                  D.Y.R. Stainier, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany   *Tg(kdrl:Hsa.HRAS-mCherry)^s896^*                                             
  (*Danio rerio*)                                                                                                                                                                                                                                           

  Strain, strainbackground\   Wnt/β-catenin reporter fish                           Francesco Argenton (University of Padua, Padova,Italy)                                    *Tg(7xTCF-Xla.Siam:GFP)^ia4^*                                                 
  (*Danio rerio*)                                                                                                                                                                                                                                           

  Antibody                    Anti-aquaporin 4 (Aqp4; rabbit, polyclonal)           EMD Millipore                                                                             AB 2218, RRID: [AB_11210366](https://scicrunch.org/resolver/AB_11210366)      1:200\
                                                                                                                                                                                                                                                            PFA fixation

  Antibody                    Anti-β-galactosidase (βGal; rabbit, polyclonal)       MP Biomedicals                                                                            \#55978                                                                       1:1000\
                                                                                                                                                                                                                                                            PFA

  Antibody                    Anti-PECAM/CD31 (rat, monoclonal)                     BD Pharmingen                                                                             \#553370, RRID: [AB_394816](https://scicrunch.org/resolver/AB_394816)         1:100\
                                                                                                                                                                                                                                                            PFA

  Antibody                    Anti-Cdh5/VE-Cadherin (goat, polyclonal)              Santa-Cruz Biotechnology                                                                  sc-6458, RRID: [AB_2077955](https://scicrunch.org/resolver/AB_2077955)        1:50\
                                                                                                                                                                                                                                                            PFA/\
                                                                                                                                                                                                                                                            MetOH

  Antibody                    c-fos (H-125) (rabbit, polyclonal)                    Santa-Cruz Biotechnology                                                                  sc-7202, RRID: [AB_2106765](https://scicrunch.org/resolver/AB_2106765)        1:1000\
                                                                                                                                                                                                                                                            PFA

  Antibody                    Anti-claudin-5/Cldn5 (rabbit, polyclonal)             Thermo Fisher Scientific                                                                  \#341600                                                                      1:200\
                                                                                                                                                                                                                                                            PFA/\
                                                                                                                                                                                                                                                            MetOH

  Antibody                    Anti-Collagen IV (rabbit, polyclonal)                 BioRad                                                                                    \#2150--1470, RRID: [AB_2082660](https://scicrunch.org/resolver/AB_2082660)   1:300\
                                                                                                                                                                                                                                                            PFA

  Antibody                    Anti-α-dystroglycan/α-Dag (mouse, monoclonal)         Novus-Biologicals                                                                         NBP1-49634, RRID: [AB_11015510](https://scicrunch.org/resolver/AB_11015510)   1:50\
                                                                                                                                                                                                                                                            PFA\*

  Antibody                    Anti-Kir4.1 (rabbit, polyclonal)                      Alomone labs                                                                              APC-035, RRID: [AB_2040120](https://scicrunch.org/resolver/AB_2040120)        1:200\
                                                                                                                                                                                                                                                            PFA\*

  Antibody                    Anti-Laminin α 2/Lama2 (rat, monoclonal)              Abcam                                                                                     ab11576,\                                                                     1:200\
                                                                                                                                                                              RRID: [AB_298180](https://scicrunch.org/resolver/AB_298180)                   MetOH

  Antibody                    Anti-occludin (mouse, monoclonal)                     Thermo Fisher (Invitrogen)                                                                \#33--1500, RRID: [AB_2533101](https://scicrunch.org/resolver/AB_2533101)     1:100\
                                                                                                                                                                                                                                                            PFA\*

  Antibody                    Anti-Plvap/Meca32 (rat, monoclonal)                   BD Pharmingen                                                                             \#553849, RRID: [AB_395086](https://scicrunch.org/resolver/AB_395086)         1:100\
                                                                                                                                                                                                                                                            PFA/\
                                                                                                                                                                                                                                                            MetOH

  Antibody                    Anti-podocalyxin/Podxl (goat, polyclonal)             R and D Systems                                                                           AF1556, RRID: [AB_354858](https://scicrunch.org/resolver/AB_354858)           1:100\
                                                                                                                                                                                                                                                            PFA/\
                                                                                                                                                                                                                                                            MetOH

  Antibody                    Anti-Sox17 (goat, polyclonal)                         R and D Systems                                                                           AF1924, RRID: [AB_355060](https://scicrunch.org/resolver/AB_355060)           1:100\
                                                                                                                                                                                                                                                            PFA

  Antibody                    Anti-ZO-1 (rabbit, polyclonal)                        Thermo Fisher (Invitrogen)                                                                \#40--2300, RRID: [AB_2533457](https://scicrunch.org/resolver/AB_2533457)     1:100\
                                                                                                                                                                                                                                                            MetOH

  Antibody                    Anti-goat IgG DyLight 550-conjugated\                 Thermo Fisher Scientific                                                                  SA5-10087, RRID: [AB_2556667](https://scicrunch.org/resolver/AB_2556667)      1:500\
                              (donkey, polyclonal)                                                                                                                                                                                                          PFA/\
                                                                                                                                                                                                                                                            MetOH

  Antibody                    Anti-goat IgG DyLight 650-\                           Thermo Fisher Scientific                                                                  SA5-10089, RRID: [AB_2556669](https://scicrunch.org/resolver/AB_2556669)      1:500\
                              conjugated\                                                                                                                                                                                                                   PFA/\
                              (donkey, polyclonal)                                                                                                                                                                                                          MetOH

  Antibody                    Anti-rabbit IgG DyLight 488-conjugated\               Thermo Fisher Scientific                                                                  SA5-10038, RRID: [AB_2556618](https://scicrunch.org/resolver/AB_2556618)      1:500\
                              (donkey, polyclonal)                                                                                                                                                                                                          PFA/\
                                                                                                                                                                                                                                                            MetOH

  Antibody                    Anti-rabbit IgG DyLight 550-conjugated\               Thermo Fisher Scientific                                                                  SA5-10039, RRID: [AB_2556619](https://scicrunch.org/resolver/AB_2556619)      1:500\
                              (donkey, polyclonal)                                                                                                                                                                                                          PFA/\
                                                                                                                                                                                                                                                            MetOH

  Antibody                    Anti-rat IgG DyLight 550-conjugated\                  Thermo Fisher Scientific                                                                  SA5-10027, RRID: [AB_2556607](https://scicrunch.org/resolver/AB_2556607)      1:500\
                              (donkey, polyclonal)                                                                                                                                                                                                          PFA/\
                                                                                                                                                                                                                                                            MetOH

  Other                       DAPI                                                  Molecular Biological Technology (Mo Bi Tec)                                               D-1306                                                                        300 µM (1:800)

  Other                       NeuroTrace^TM^Green Fluorescent Nissl Stain           Thermo Fisher Scientific                                                                  N21480                                                                        1:300\
                                                                                                                                                                                                                                                            PFA

  Other                       Tissue-Tek O.C.T.                                     Sakura Finetek Europe                                                                     4583                                                                          

  Other                       qPCR SYBR Green Fluorescein Mix                       Thermo Fisher Scientific                                                                  AB-1219                                                                       

  Chemicalcompound            Tricaine methanesulfonate (MS-222)                    Sigma-Aldrich                                                                             E10521                                                                        

  Chemical\                   TAM                                                   Sigma-Aldrich                                                                             T5648                                                                         
  compound                                                                                                                                                                                                                                                  

  Chemicalcompound            FITC-albumin                                          Sigma-Aldrich                                                                             \#A9771                                                                       

  Chemicalcompound            tomato lectin Alexa 649                               Vector laboratories                                                                       (\#DL-1178                                                                    

  Chemicalcompound            ethylcinnamate (ECi),)                                Sigma-Aldrich                                                                             (\#112372                                                                     

  Chemicalcompound            AR6 Buffer                                            Perkin Elmer                                                                              (\#AR600250ML                                                                 

  Commercial kit              RNeasy plus Micro kit                                 Qiagen                                                                                    \#74034                                                                       

  Commercial kit              RevertAidTM H minus first strand cDNA synthesis kit   Thermo Fisher Scientific                                                                  \#K1632                                                                       

  Commercial kit              RNeasy Mini kit                                       Quiagen                                                                                   \#74104                                                                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animal models {#s4-1}
-------------

Mice were housed under standard conditions with 12 hrs light dark cycle and water and mouse chow available *ad libitum* if not declared otherwise. All experimental protocols, handling and use of mice were approved by the Regional Council Darmstadt, Germany (V54-19c20/15-FK/1052 and V54-19c20/15-FK/1108). Wildtype (WT) C57BL6/J as well as transgenic animals were used. The following mouse strains were included Cdh5(PAC)-CreERT2 ([@bib57]), PDGFB-iCreERT2 ([@bib8]), Ctnnb1^Ex3fl/fl^ ([@bib20]), BAT-gal^+/wt^ Wnt/β-catenin reporter ([@bib33]) and *mT/mG* ([@bib41]).

Zebrafish (*Danio rerio*) were maintained under standard conditions at 28°C and a 14 hr light/10 hr dark cycle, in accordance with European and national animal welfare and ethical guidelines (protocol approval number: CEBEA-IBMM2017-22:65). Transgenic lines used in this study were Tg(kdrl:Hsa.HRAS-mCherry)^s896^ ([@bib6]) and Tg(7xTCF-Xla.Siam:GFP)^ia4^ ([@bib39]). After euthanasia with 0.3 mg.ml-1 Tricaine methanesulfonate (MS-222) for 10 min, adult brains aged 6 to 12 months were dissected and fixed overnight in sweet fixative (4% PFA, 4% sucrose in PBS). Brains were washed in PBS and embedded in 4% low-melting agarose. 300 μm sections were obtained using a LeicaVT1200s automated vibratome (Leica Biosystems). Sections were imaged on a Zeiss LSM710 confocal microscope using separate channels.

Development assays {#s4-2}
------------------

To investigate β-catenin activity in ECs, Wnt/β-catenin reporter mice (BAT-gal^+/wt^) were bred with C57BL6/J mice to generate either heterozygous positive pups for β-galactosidase or homozygous negative control littermates. At different developmental stages (embryonic days E13.5, E17.5) embryos were harvested. For postnatal day 0 (P0) pups were sacrificed by decapitation, for postnatal day 21 (P21) pups were sacrificed by cervical dislocation. Brain preparation was performed in ice cold PBS and followed by overnight fixation in 4% PFA in PBS. For cryo-sectioning the whole brain was embedded in Tissue-Tek O.C.T. after incubation in 12/15/18% sucrose.

Tightening of SFO vessels {#s4-3}
-------------------------

β-Catenin endothelial specific gain of function system was kept by the use of Ctnnb1^Ex3fl/fl^ ([@bib20]) mice crossed with the Cdh5(PAC)-CreERT2 ([@bib57]). To activate the Cre-recombinase, tamoxifen (TAM, 500 µg/day in corn oil; central pharmacy, Steinbach, Germany) was i.p. injected on five consecutive days. Brains were harvested and embedded for cryo-sectioning at 16, 19 and 26 days after the first TAM injection. To investigate the tightening effect at different postnatal stages, pups were i.p. injected with TAM (50 µg/day in corn oil) at P0-P3 and analyzed on P6 and P14.

Tracer experiments {#s4-4}
------------------

Animals were injected with TAM and kept for 26 days to assure SFO vessel tightening as described above. Mice were anesthetized and intravenously injected with 50 µl FITC-albumin (\#A9771; Sigma-Aldrich). After 1.5 hr mice were sacrificed by cervical dislocation. The embedded brain was cryo sectioned (20 µm, counterstained for Podxl and analyzed after confocal imaging. For analysis the FITC covered area as well as the Podxl^+^ vessel area within the SFO was measured for each optical section of at least one stack. To quantify the tracer leakage, the FITC covered SFO area was normalized to the vessel area, indicated by Podxl staining.

Thirst inducing experiments {#s4-5}
---------------------------

### Water restriction {#s4-5-1}

To induce thirst, animals were water restricted for 72 hr. Therefore, the animals had no free access to water and got only a restricted amount of water every 24 hr according to their initial body weight ([Table 1](#table1){ref-type="table"}). During the experimental period the body weight is stable between at least 80--85% of the initial weight at day 0. After 72 hr there was no more water provided to keep the thirsty state. Mice were sacrificed and SFO tissue analyzed for c-fos as an immediate early gene marker for neuronal activity. The neuronal identity of c-fos^+^ cells was confirmed by fluorescent Nissl co-staining (Key resource table).
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###### Documentation of water provided to mice according to their body weight in the water restriction paradigm

  Bodyweight (BW)    Offered water \[ml\]
  ------------------ ----------------------
  BW \> 84%          1.1
  84% \> BW \> 83%   1.2
  83% \> BW \> 82%   1.3
  82% \> BW \> 81%   1.4
  81% \> BW          1.5

Hyperosmolar NaCl injection {#s4-6}
---------------------------

Mice were i.p. injected with either 3 M or an isotonic (0.15 M) NaCl solution (150 µl/20 g mouse) as described in Zimmerman et al. ([@bib61]). After an incubation time of 50 min without any access to drinking water animals were sacrificed and SFOs were analyzed in cryo sections for c-fos activation.

SFO whole mount for light sheet microscopy {#s4-7}
------------------------------------------

### Sample preparation {#s4-7-1}

To label blood vessels, 80 µl tomato lectin Alexa 649 (\#DL-1178, Vector laboratories) were injected i.v. in adult mice. After 4 min of circulation time animals were sacrificed by cervical dislocation. After overnight fixation (4% PFA in PBS) whole mount tissue samples were blocked and permeabilized with 0.2% gelatin from bovine skin, Type B, 0.5% Triton in PBS from 24 hr up to one week according to their size. Antibodies (Key resource table) were applied in blocking buffer supplemented with 0.1% saponin. To fix the staining samples were incubated for one hour in 4% PFA.

Tissue dehydration and clearing {#s4-8}
-------------------------------

At first the tissue was embedded in low melt agarose. The following dehydration and delipidation protocol was adapted from Orlich et al. and Renier et al. ([@bib44]; [@bib48]). In brief, MetOH (50/70/100%) in PBS was used for 1 hrs for each step in dark-brown glass vials slightly shaking at RT, followed by an overnight incubation in 100% MetOH. To remove lipids an incubation with dichlormethane followed until the tissue sank down. Afterwards ethylcinnamate (ECi) (\#112372, Sigma-aldrich) clearing was performed as described in Klingberg et al. ([@bib25]). Samples were stored in ECi solution that was renewed one day before the acquisition. Samples were imaged in ECi solution with an UltraMicroscope II (LaVision, Germany) and stacks with 1 µm step size were further processed for visualization either by Imaris 9 (BitPlane, Switzerland) or the volume visualization framework Voreen (volume rendering engine) ([@bib36]).

Immunohistochemical staining {#s4-9}
----------------------------

Either native frozen tissue or sucrose embedded samples were cryo-sectioned coronal or sagittal in 10 µm thickness and then fixed with 4% PFA for 10 min at room temperature or with ice cold MetOH for 3 min. To block/permeabilize tissue slides were incubated for 1 hr (overnight for vibratome section) (10% NDS, 0.1% Triton-X100 in PBS). Primary antibodies (Key resource table) were incubated for 2 hr (24 hr for vibratome section) and secondary for 1 hr (4 hr for vibratome section) in antibody incubation buffer (1% BSA, 0.1% Triton-X100 in PBS). If required, sections of PFA-fixed samples were subjected to antigen-retrieval (\*) by boiling slides for 45 min in AR6 Buffer (\#AR600250ML; Perkin Elmer). After cooling them down and an additional washing step, slides were stained as described above.

Image acquisition and analysis of cryo-sections {#s4-10}
-----------------------------------------------

Images were acquired using either a Nikon 80i wide field fluorescent microscope, or a Nikon C1si Confocal Laser Scanning Microscope, together with NIS-Elements Microscope Imaging Software for image analysis (Nikon Instruments, Inc., Düsseldorf, Germany). SFO vessels were defined as regions of interest (ROI) for area measurements. Staining was evaluated as a ratio of Cldn5 or Plvap/Meca32 to vessel area, evidenced by Podxl or Cdh5 labeling.

The number of c-fos^+^ neurons as well as the total number of nuclei within the SFO, defined as ROI, were counted and the ratio of c-fos + to total nuclei was calculated.

Electron microscopy {#s4-11}
-------------------

Animals were anesthetized and transcardially perfused with PBS/heparin for 1 min followed by 4 min with 4% PFA in cacodylate buffer (CB, pH 7.4). The SFO was whole mount prepared in ice cold PBS directly after brain isolation. Afterwards the tiny SFO whole mount tissue pieces were post-fixed with 4% PFA and 2% glutaraldehyde/CB overnight at 4°C.

Prior to embedding the tissue was incubated in 1% Os for 2 hr at RT followed by dehydration in graded acetone including contrast enhancement with uranyl acetate solution at 4°C o/n. Samples were embedded in Epon finally polymerized at 60°C for 24 hr. Ultra-thin sections (50 nm) were cut with Leica Ultracut UCT and analyzed using a Tecnai Spirit BioTWIN FEI electron microscope at 120kV. Images were taken with an Eagle 4K CCD bottom-mount camera. For the quantification of fenestrations, 5 SFO vessels were analyzed for each animal (n = 4 per genotype).

RNA isolation, transcription and real time PCR analysis {#s4-12}
-------------------------------------------------------

RNA isolation was done using the RNeasy plus Microkit (Qiagen) according to the manufacturer recommendations with DNase on-column digestion (Qiagen) like suggested in the RNeasy Minikit (Quiagen). For cDNA synthesis (RevertAidTM H minus first strand cDNA synthesis kit, \#K1632, Thermo Fisher Scientific) 57 ng RNA were used from SFO tissue of β-catenin GOF (Cre^+^) and control (Cre^-^) mice.

Quantitative real time RT-PCR (qRT-PCR) was performed in technical triplicates for each sample using the Absolute qPCR SYBR Green Fluorescein Mix (AB-1219, Thermo Fisher Scientific) according to the manufacturer\'s protocol. Rplp0 was used as a housekeeping gene for normalization. Expression data were analyzed with ∆∆ct method. Primer sequences used for cDNA amplification by qRT-PCR are listed in [Table 2](#table2){ref-type="table"}.
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###### List of primers used for real time PCR.

  Primer for   Sequence 5\'−3' sense    Sequence 5'−3' antisense
  ------------ ------------------------ --------------------------
  qmm_Cldn5    TGTCGTGCGTGGTGCAGAGT     TGCTACCCGTGCCTTAACTGG
  qmm_Meca32   CTTCATCGCCGCTATCATCCT    CCTTGGAGCACACTGCCTTCT
  qmm_Rplp0    GTGTTTGACAACGGCAGCATT    TCTCCACAGACAATGCCAGGA
  qmm_Ocln     GTGAATGGCAAGCGATCATACC   TGCCTGAAGTCATCCACACTCA

Statistical analyses {#s4-13}
--------------------

No statistical tests were used to predetermine sample size. Several independent experiments were performed to ensure reproducibility. The investigators were blinded by the experimental design during the analysis of the experiments shown in [Figures 4E](#fig4){ref-type="fig"}, [5F--H](#fig5){ref-type="fig"}, [6D](#fig6){ref-type="fig"}, [7E--F](#fig7){ref-type="fig"} and [8C](#fig8){ref-type="fig"} as well as in [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}, [Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}, [Figure 7---figure supplement 2B](#fig7s2){ref-type="fig"}. Raw data are presented in the additional source data files.

The number of biological replicates is provided as 'n' in the legend of each figure. Technical replicates, such as the number of sections analyzed or replicates for qRT-PCR analyses are indicated in the figure legend and the respective material and methods section, respectively. Results are shown as mean ±SEM. Statistical significance was assessed by an unpaired t-test using GraphPad Prism version 6.0 (GraphPad Software Inc., USA). p-Values were considered significant at p\<0.05 and individual p-values are provided in each figure.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Low Wnt/β-catenin signaling determines leaky vessels in the subfornical organ and affects water homeostasis in mice.\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Elisabetta Dejana as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by K VijayRaghavan as the Senior Editor. The following individuals involved in the review of your submission have agreed to reveal their identity: Dritan Agalliu (Reviewer \#2); Christer Betsholtz (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. The reviewers have found your paper of interest and potentially acceptable for publication in *eLife*. However, all the three referees raise important points to be considered before acceptance.

Summary:

The paper from Liebner laboratory investigates how CVO vessels, known to lack BBB and be permeable to water, solutes, and hormones, are regulated in relation to Wnt/β-catenin signaling -- a central inducer of the BBB. The authors find (1) using Wnt reporter technologies, that Wnt signaling is undetectable in CVOs throughout development in mice and in adult zebrafish. (2) They describe a cellular phenotypic heterogeneity in the CVO vessels regarding Plvap and Cldn5 expression and they suggest that the latter might be regulated in a circadian fashion. (3) Using an inducible genetic β-catenin GOF approach, they show conversion of the CVO vessel phenotype into a BBB-like phenotype. (4) They show results that may indicate that this conversion has consequences for neuronal activity in the CVO.

This manuscript is an interesting and valuable contribution to the field that deserves publication in *eLife*. The manuscript is well-written and well-illustrated in general.

While going through the comments, please note in particular:

Additional controls for the role of canonical Wnt/β-catenin signaling in the observed control of permeability are asked for. If experimentally feasible, an earlier control of β-catenin signaling in SFO would also be important. Please see if these are speedily do-able and if not pleased adequately discuss these points. It will be useful to have this experimentally addressed, though.

A more accurate analysis of the permeability properties of SFO vessels and of tight junction organization and more accurate analysis of astrocyte polarization and matrix protein organization are also asked. More specifically, the authors should make better images for their c-fos data and show that it is indeed neurons that express c-fos.

The authors could remove the circadian Cldn5 data (premature), the Aqp4 and CD13 data (confusing).

Essential revisions:

The gain-of-function mutation of β-catenin is induced in endothelial cell specifically. It is known that endothelial cells can produce soluble neural mediators. An important question, therefore, is whether the observed neural hyperactivation in vivo, induced by β-catenin gain of function in endothelial cells, is due to reduced vascular permeability or to a change of endothelial cell angiocrine activity. This is a crucial aspect for a correct interpretation of the results. Would the authors be able to see the same c-fos upregulation in neural cells by limiting permeability with different tools? For instance, mice Meca32- PLVAP knock out? Src inhibitors? VEGF inhibitors? other more specific tools? If this these experiments are not speedily addressable, they should be carefully and frontally discussed.

A point that should be clarified is whether β-catenin does not play any role in the early angiogenesis of the SFO. The authors could not see, using reporter mice, a significant increase in β-catenin activity of the SFO-endothelial cells starting from 13.5E. However, β-catenin may be important in the very first steps of angiogenesis of SFO and then decline, as it occurs in other regions of the brain microcirculation. It could be, therefore, that it is already undetectable at E13.5 while active at earlier times. This is not irrelevant to understand SFO vascularization mechanisms and function. Here too, if experiments to address this are not speedily feasible, please discuss this point adequately.

A major functional feature of the BBB is to exclude various circulating molecules from entering the CNS. However, a functional assessment of barrier properties in SFO blood vessels after β-catenin stabilization is missing. The authors need to inject intravenously small or large MW tracers and assess their permeability into the SFOs under conditions of Wnt/β-catenin activation in endothelial cells.

Does overexpression of a stabilized form of β-catenin in the adult mice induce expression of Claudin-5 and suppresses MEca32 at the SFO?

Do the blood vessels in SFO acquire Occludin protein expression at cell junctions with β-catenin overexpression? The authors need to show some staining with Occludin antibodies.

The TEM data, clearly show that in GFO mice, pericytes and astrocytes are in close contact with endothelial cells. However, astrocytes do not appear to be polarized (AqP4 is expressed all over the parenchyma, rather than restricted to blood vessels). Are other astrocyte polarity markers (e.g. Dystroglycan or Kir 4.1) absent in this region?

One potential explanation for the observation that astrocytes do not form proper endfeet in the SFO region could be due to the absence of basement membrane proteins. The authors need to examine the expression of some of the key basement membrane proteins such as Collagen IV, Laminin α2 etc.

The authors nicely demonstrate that β-catenin GOF mice have higher c-Fos levels with water restriction than wild-type mice. Underwater restrictions, mice may show abnormal behaviors under specific behavioral tasks (e.g. Goltstein et al., 2018). It may be useful to test if there are any potential behaviors (e.g. rewarding behaviors) where GOF mice may perform worse than wild-type mice due to higher c-Fos activation.

The evidence for circadian regulation of Cldn5 expression weak. While the quantifications in Figure 4E may appear convincing, the immunostainings shown in Figure 4A-D are not convincing. The amount of vasculature captured in each section appears hugely variable and the Podxl staining for endothelium seems highly variable in strength. Podxl should be luminal and Cldn5 junctional (or is it?) and this is not at all apparent at the magnification shown. Also, if true, the circadian variation in Cldn5 immunoreactivity raises a number of important issues that should be addressed, including if it is junctional or non-junctional Cldn5 that varies, if the effect is transcriptional or not if other tight junction proteins such as occludin and ZO-1 are also regulated, and more. If it is true that TJs are regulated in a circadian fashion, it is obviously interesting, but the physiological consequences are unclear, given that Plvap expression is maintained, and therefore (presumably) fenestrations not regulated. Would TJ regulation matter for the permeability if fenestrations are kept? The authors speculate that the (possible) circadian regulation of Cldn5 could influence the circadian regulation of thirst and drinking behavior, but this is pure speculation, as far as I can judge. Again, how can Cldn5 matter on top of (presumably) open fenestrations? Given the many questions and the premature nature of this data, we suggest they be removed from the present manuscript, to allow a better focus on Wnt/β-catenin regulation of the CVO vessel phenotype. If Wnt signaling is involved in the circadian regulation of Cldn5 expression in CVO vessels, it would also make more sense to study short term effects of β-catenin GOF experiments; now the earliest time point studied in adults is 16 days following induction.

Another area where conclusions are weak relates to the TEM analysis (Figure 6). The images shown do not appear to support the conclusions that vessels in the GOF mice are slimmer, less tortuous and have less ECM deposition. For the ECM, it does appear denser in GOF but this may reflect decreased water content of the ECM rather than a decreased amount of ECM per se.

The data regards c-fos expression by neurons in the SFO are also an area where the conclusions do seem robust. Neuronal staining to show that this is neuronal and not glial localization is not there. Also, some of the staining patterns are puzzling. Should not c-fos should look similar at 0h and isotonic NaCl panels in Figure 7, but they look hugely different, casting doubt over the quantifications in Figure 7E and F.

The authors find increased expression of Sox17 along with Cldn5 in GOF experiments and note in conjunction with the TEM data that this may signify arterial specification. However, this is unfounded speculation in my opinion. There are many markers for arterial EC in the brain (see Vanlandewijck et al., 2018) and Sox17 is not a particularly strong one. The authors should remove this statement or investigate possible arterialization more thoroughly.

The authors investigate Aqp4 and CD13 staining patterns to check \"other phenotypic BBB features\", but although neither Aqp4 nor CD13 was found changed in the GOF situation, it is unclear why the experiments were done in the first place. In what way do the (negative) data display an absence of BBB features? The meaning of the homogenous-looking Aqp4 staining in the CVOs is interesting but may have nothing to do with the absence of a BBB. Does the staining reflect lack of end-foot restricted localization in astrocytes, or is it the tanycytes that express Aqp4 in the CVOs? Also, what does the CD13-staining mean? Is this mural cells or perivascular fibroblasts (see Vanlandewijck et al., 2018)?

10.7554/eLife.43818.044

Author response

> Essential revisions:
>
> The gain-of-function mutation of β-catenin is induced in endothelial cell specifically. It is known that endothelial cells can produce soluble neural mediators. An important question, therefore, is whether the observed neural hyperactivation in vivo, induced by β-catenin gain of function in endothelial cells, is due to reduced vascular permeability or to a change of endothelial cell angiocrine activity. This is a crucial aspect for a correct interpretation of the results. Would the authors be able to see the same c-fos upregulation in neural cells by limiting permeability with different tools? For instance, mice Meca 32- PLVAP knock out? src inhibitors? VEGF inhibitors? other more specific tools? If this these experiments are not speedily addressable, they should be carefully and frontally discussed.

We thank the reviewer for getting into this discussion. Indeed, it is difficult, if not impossible to dissect the two effects downstream of β-catenin activation, namely the physical tightening of SFO vessels and the direct effects on endothelial cells, including their autocrine status.

![8 week-old female C57Bl6 mice were treated by i.p. injections of 1mg/kg BIO-X/DMSO every third day for 21 days.\
For the final 72 hours, mice were water-deprived and subsequently sacrificed and analyzed for Meca32 as well as for Cldn5 (n=10). Representative immunofluorescent images (**A**). Quantification of Meca32- and Cldn5-covered vessel area within the SFO (**B**). Error bars show ± SEM. Scale bars represent 100 µm.](elife-43818-resp-fig1){#respfig1}

Because of the time constraints of the revision period, we could not establish genetic mouse models for Meca-32/Plvap deletion in endothelial cells.

Although thoroughly addressing this question in vivo is a project on its own and would be beyond the scope of this manuscript, we have made an effort to repeat the water restriction experiments, using the Wnt pathway activator BIO-X ([Author response image 1](#respfig1){ref-type="fig"}) as well as the Scr-inhibitor AZD0530 ([Author response image 2](#respfig2){ref-type="fig"}).

We systemically administered BIO-X by i.p. injections of 1mg/kg BIO-X/DMSO every third day for 21 days. For the final 72 hours, mice were water-deprived and subsequently sacrificed and analyzed for Meca32 as well as for Cldn5. Unfortunately, we cloud not detect significant down regulation of Meca32 and up regulation of Cldn5 in SFO vessels. Instead, the phenotype of physiologically leaky vessels persisted.

Similar results were obtained, when mice were daily treated with 25mg/kg AZD0530 Scrinhibitor by oral gavage for 7 days. Scr inhibition did not result in any effects on Meca32 and Cldn5 expression evidenced by IF staining. Analysis of c-fos showed the expected increased staining in the SFO of water-restricted mice (data not shown).

![8 week-old female C57Bl6 mice were mice were daily treated with 25mg/kg AZD0530 Scr-inhibitor by oral gavage for 7 days.\
For the final 72 h, mice were water-deprived and subsequently sacrificed and analyzed for Meca32 as well as for Cldn5 (n=10). Representative immunofluorescent images (**A**). Quantification of Meca32- and Cldn5-covered vessel area within the SFO (**B**). Error bars show ± SEM. Scale bars represent 100 µm.](elife-43818-resp-fig2){#respfig2}

Currently, we are further analyzing the samples of the BIO-X- and AZD0530-treated mice for activation of β-catenin, by staining for nuclear β-catenin as well as for Lef-1, which will be informative for future experiments but will not be relevant for the revision of the present manuscript. Additional experiments with other compounds such as VEGF-inhibitors could not be performed due to time limitation.

To understand if activation of the Wnt/β-catenin pathway in ECs may alter their angiocrine profile, we have analyzed as a first step primary mouse brain microvascular endothelial cells (pMBMECs) that were stimulated with either Wnt3a or PBS/BSA control. Given the importance of vascular endothelial growth factor A (VEGFA) for neuronal function ("neurogenesis, neuronal migration, neuronal survival and axon guidance", Mackenzie and Ruhrberg, 2012), we analysed VEGFA expression in Wnt-activated ECs by qRT-PCR. Despite robust induction of Axin2 as a well-established Wnt/β-catenin target, we did not observe a concomitant VEGFA regulation ([Author response image 3](#respfig3){ref-type="fig"}).

![pMBMECs were isolated and cultivated as previously published (Ziegler et al., 2016; Liebner et al., 2008), and after one passage stimulated for 9 days with 150mM recombinant mouse Wnt3a (\#315-20, Peprotech).\
Total RNA was harvested (n=2), converted into cDNA and subjected to qRT-PCR analysis.](elife-43818-resp-fig3){#respfig3}

> A point that should be clarified is whether β-catenin does not play any role in the early angiogenesis of the SFO. The authors could not see, using reporter mice, a significant increase in β-catenin activity of the SFO-endothelial cells starting from 13.5E. However, β-catenin may be important in the very first steps of angiogenesis of SFO and then decline, as it occurs in other regions of the brain microcirculation. It could be, therefore, that it is already undetectable at E13.5 while active at earlier times. This is not irrelevant to understand SFO vascularization mechanisms and function. Here too, if experiments to address this are not speedily feasible, please discuss this point adequately.

We thank the reviewer for this comment. We completely agree and have also analyzed earlier stages of BAT-gal reporter mice however, E13.5 was the earliest timepoint at which we could identify and visualize the developing SFO. Indeed, at this timepoint angiogenesis of the SFO is ongoing. Still, we could not observe active Wnt/β-catenin signaling. Consequently, due to the fact that E13.5 was the earliest timepoint the SFO is identifiable, we could not go earlier in order to study Wnt/β-catenin activation. Maybe we haven't made this point as clear as it should be. We have now introduced this explanation in the Results section. We hope that this clarifies the reviewer's question.

> A major functional feature of the BBB is to exclude various circulating molecules from entering the CNS. However, a functional assessment of barrier properties in SFO blood vessels after β-catenin stabilization is missing. The authors need to inject intravenously small or large MW tracers and assess their permeability into the SFOs under conditions of Wnt/β-catenin activation in endothelial cells.

We thank the reviewer for this important comment. The physiological assessment of barrier tightness is indeed one of the most relevant parameters to address changes in permeability. In order to tackle the reviewer's comment, we have injected β-catenin GOF and controls with tamoxifen, waited for 26 days and injected the mice intravenously with FITC-BSA (\~68 kDa) and 3 kDa TMR-dextran. The detailed procedure is incorporated in the Material and Methods section of the revised manuscript. We now describe that the permeability for FITC-BSA was significantly reduced in the GOF compared to control animals. This result is now shown in Figure 6. Unfortunately, we encountered technical problems with a new Lot of the 3kDa TMR-dextran tracer that, although injected the same way as the FITC-BSA tracer, did not reveal the vessels nor was it detectable in the parenchyma of the SFO and other CVOs. For the reviewers' reference, we show the positive technical pilot with an older Lot, nicely demonstrating leakage of the small tracer ([Author response image 4A](#respfig4){ref-type="fig"}). Unfortunately, the two experiments with the new Lot of the tracer failed and due to the restricted availability of double transgenic mice and of time for the revision we were not able to repeat this experiment.

We hope that the reviewers feel that we have sufficiently shown the physiological tightening of SFO vessels by the reduced leakiness of the \~68 kDa tracer and it clarifies the reviewers' question.

![3 kDa TMR-dextran tracer was injected iv (150µl of a 2mM solution in PBS) into C56Bl6 WT mice for the pilot experiment (**A**), or iv into Ctrl and GOF mice in case of the real experiment (**B**).\
In the pilot experiment vessels were nicely filled and labeled by 3 kDa TMR-dextran (arrows). In the SFO (dashed line) tracer extravasation was visible. In the experiment with Ctrl and GOF mice, the tracer was not visible in the vessel lumen, although successful iv injection was confirmed by the larger tracer (FITC-BSA, main Figure 6).](elife-43818-resp-fig4){#respfig4}

> Does overexpression of a stabilized form of β-catenin in the adult mice induce expression of Claudin-5 and suppresses MEca32 at the SFO?

We thank the reviewer for this question. It might be that we were not clear enough in the original submission of our manuscript, but the data that we've presented in the original Figure 5 (now Figure 4 in the revised manuscript) were derived from adult double transgenic mice. We have now clarified this in the figure legend as follows: "(A) Mouse model and (B) schedule of endothelial-specific β-catenin GOF induction by tamoxifen (TAM) in adult, 8-12 week old mice".

Additionally, we have added data on the RNA expression of occludin (Ocln), showing in Figure 5 of the revised manuscript similarly to Cldn5 no mRNA upregulation could be observed, although Meca32 was significantly decreased in the SFOs of β-catenin GOF mice. Although the lack of transcriptional regulation of the two junctional genes may suggest that they are no direct targets of βcatenin, we might also face problems of signal masking by tight vessels in the total RNA, isolated from whole mount preparations. We now discuss this in the Discussion section and suggest that future RNAseq analysis of FACS-sorted pools and/or single cells may help to answer this question.

> Do the blood vessels in SFO acquire Occludin protein expression at cell junctions with β-catenin overexpression? The authors need to show some staining with Occludin antibodies.

We thank the reviewer for this comment. We have investigated occludin (Ocln) expression and localization in SFO vessels of β-catenin GOF and control mice. The staining procedure and the antibody is incorporated in the Material and methods section of the revised manuscript. We now show that beside Cldn5, also Ocln localization at cell-cell junctions is significantly increased in GOF mice (Figure 5 of revised manuscript). Additionally, we have analyzed the expression of Ocln on the mRNA level by qRT-PCR and now show that in line with the expression of Cldn5 also the RNA of Ocln was not significantly increased in the SFO of GOF mice. As mentioned above, this might be due to the masking of the specific endothelial RNA by the total RNA isolated from the whole mount preparations, which inevitably include the ependymal epithelium that also expresses Ocln. Analyzing FACS-sorted cells from the SFO unfortunately, was beyond the scope of the present work.

In addition to Ocln, we have now also stained for the adherens and tight junction associated protein zonula occludens/tight junction protein 1 (ZO-/Tjp1), which we now show in Figure 5---figure supplement 1. As opposed to Cldn5 and Ocln, for ZO-1 we observed only a minor increase in junctional continuity of ZO-1 staining. This finding fits with a comparable distribution of VE-cadherin/Cdh5 in GOF and control vessels in the SFO (Figure suppl. 4), given that ZO-1 was shown to localize to adherens junctions if tight junctions are weak or absent (Tornavaca et al., 2015). This is now discussed in the Discussion section.

> The TEM data, clearly show that in GFO mice, pericytes and astrocytes are in close contact with endothelial cells. However, astrocytes do not appear to be polarized (AqP4 is expressed all over the parenchyma, rather than restricted to blood vessels). Are other astrocyte polarity markers (e.g. Dystroglycan or Kir 4.1) absent in this region?

We thank the reviewer for bringing up this interesting issue. By showing the staining of Aqp4 for astrocytic endfeet and by CD13 for pericytes, our intention was to visualize potential changes to the entire neuro-vascular unit (NVU) in SFO vessels of β-catenin GOF compared to control mice. That the leaky vessels of the mouse SFO do not exhibit an organization as an NVU was previously shown by Pócsai et al., (2015). Indeed, we could not observe Aqp4 polarisation at astrocytic endfeet in the control conditions, but equally not along with barrier tightening in GOF mice. As suggested by the reviewer we now investigated the polarisation markers α-dystroglycan (α-Dag) and Kir4.1 and obtained comparable results now shown in Figure 7---figure supplement 1 of the revised manuscript, suggesting that end feet polarization does not follow endothelial tightening. Specifically, dystroglycan shows weak and not strictly polarized staining around SFO vessel, whereas Kir4.1 seems to be mainly expressed by cells morphologically resembling tanycytes in the SFO. The co-localized distribution of dystroglycan and Kir4.1 around BBB vessels nicely confirmed the specific staining of these markers. This was not only true 26 days after TAM injection but also after 60 day, supporting the interpretation that the proper cellular arrangement of the NVU requires additional cues than endothelial Wnt/β-catenin signaling.

> One potential explanation for the observation that astrocytes do not form proper endfeet in the SFO region could be due to the absence of basement membrane proteins. The authors need to examine the expression of some of the key basement membrane proteins such as Collagen IV, Laminin α2 etc.

We thank the reviewer for this thoughtful comment. We have investigated collagen IV, laminin α2 (Lama2) with specific antibody staining in SFO vessels of β-catenin GOF and control mice. The staining procedure and the antibodies are incorporated in the Material and methods section of the revised manuscript. We now show that collagen IV and Lama2 are indeed expressed around SFO vessels, and their distribution and localization follows the outline of the vessels. At least from these observations we concluded that the lack of proper astrocytic endfoot formation around SFO vessels has no obvious correlation to a lack of the most abundant basement membrane components. These findings are shown in the revised manuscript in Figure 7---figure supplement 2.

> The authors nicely demonstrate that β-catenin GOF mice have higher c-Fos levels with water restriction than wild-type mice. Underwater restrictions, mice may show abnormal behaviors under specific behavioral tasks (e.g. Goltstein et al., 2018). It may be useful to test if there are any potential behaviors (e.g. rewarding behaviors) where GOF mice may perform worse than wild-type mice due to higher c-Fos activation.

We thank the reviewer for this mindful comment. In the manuscript by Goldstein et al. the authors strictly compare food versus water restricted animals in their behaviour and conclude that there are little to no dramatic changes in overall behaviour due to water restriction. Specifically, water-deprived mice perform better regarding rewarding behaviour than food-deprived mice.

In order to tackle the reviewer's request, we contacted our collaborators Prof. Jochen Roeper and Dr. Natascha Diamantopoulou (Institute of Neurophysiology, Goethe University Frankfurt), with which we have already planned to investigate the impact of SFO vessel tightening on mouse drinking behaviour. It turned out that it was not feasible to establish and conduct a meaningful experiment within the two month revision timeframe, considering 26d of TAM induction, mouse adaptation and taming, as well as water deprivation and analysis. Although testing the behaviour of Ctrl and GOF mice is beyond the scope of the present study, we believe however, that there is good evidence, that the overall rewarding behaviour does not play a major role in our paradigm. This has been shown and discussed in Augustine et al., 2018, who stated that activation of neurons in the median preoptic nucleus (MnPO), as part of the terminal lamina "indicate that MnPO^GLP1R^ neurons are activated purely by fluid consumption and not by reward-seeking behaviour or licking action per se. Consistent with the connection from MnPO^GLP1R^ to SFO^nNOS^ neurons, the activity of the SFO^nNOS^ population mirrored precisely the calcium dynamics of MnPO^GLP1R^ neurons". The findings of Augustine et al. may therefore support our interpretation that, the increase in c-fos in the SFO of GOF water-deprived mice, relates to altered water homeostasis rather than altered overall behaviour. Moreover, we learned from our collaborators, that water deprivation as a widely used paradigm to augment the motivation of mice and other rodents, is not considered to lead to "abnormal" behaviour, given that water and food deprivation is the „normal "situation in wild mice, whereas water and food ad libitum could be rather considered as abnormal.

Nevertheless, we would like to emphasis that the question raised by the reviewer is very valid and that it was and is on our future agenda as it requires substantial expertise in behavioural sciences and adequate equipment (both will be provided by the group of Prof. Roeper). We hope the reviewers appreciate the limitations we faced regarding this question and leave the answer to future work.

> The evidence for circadian regulation of Cldn5 expression weak. While the quantifications in Figure 4E may appear convincing, the immunostainings shown in Figure 4A-D are not convincing. The amount of vasculature captured in each section appears hugely variable and the Podxl staining for endothelium seems highly variable in strength. Podxl should be luminal and Cldn5 junctional (or is it?) and this is not at all apparent at the magnification shown. Also, if true, the circadian variation in Cldn5 immunoreactivity raises a number of important issues that should be addressed, including if it is junctional or non-junctional Cldn5 that varies, if the effect is transcriptional or not if other tight junction proteins such as occludin and ZO-1 are also regulated, and more. If it is true that TJs are regulated in a circadian fashion, it is obviously interesting, but the physiological consequences are unclear, given that Plvap expression is maintained, and therefore (presumably) fenestrations not regulated. Would TJ regulation matter for the permeability if fenestrations are kept? The authors speculate that the (possible) circadian regulation of Cldn5 could influence the circadian regulation of thirst and drinking behavior, but this is pure speculation, as far as I can judge. Again, how can Cldn5 matter on top of (presumably) open fenestrations? Given the many questions and the premature nature of this data, we suggest they be removed from the present manuscript, to allow a better focus on Wnt/β-catenin regulation of the CVO vessel phenotype. If Wnt signaling is involved in the circadian regulation of Cldn5 expression in CVO vessels, it would also make more sense to study short term effects of β-catenin GOF experiments; now the earliest time point studied in adults is 16 days following induction.

![TEM images of SFO vessels taken from βcatenin control and GOF mice (26d after TAM injection) were analysed for vessels perimeter by measuring the perimeter of vessel using the polygon tool in ImageJ.\
In total 14 and 10 vessels were analysed for control and GOF, respectively. n=3; unpaired student t test was applied.](elife-43818-resp-fig5){#respfig5}

We thank the reviewers for this important comment. As suggested by the reviewers, we have removed the data on circadian regulation from the revised manuscript. Based on the other recommendations of the reviewers, we have now set Figure 5 of the original manuscript as Figure 4 and have included the novel data on occludin (Ocln) localisation and expression in SFO vessels of β-catenin GOF and control mice as Figure 5. We further thank the reviewer for the constructive suggestions on analyzing earlier time point after TAM induction, which we will consider in ongoing experiments

> Another area where conclusions are weak relates to the TEM analysis (Figure 6). The images shown do not appear to support the conclusions that vessels in the GOF mice are slimmer, less tortuous and have less ECM deposition. For the ECM, it does appear denser in GOF but this may reflect decreased water content of the ECM rather than a decreased amount of ECM per se.

We thank the reviewer for this comment. As the description of vessels diameter and morphology in the TEM analysis was not based on any quantifications, we have analysed the vessel perimeter but could not identify a significant effect on vessel perimeter ([Author response image 5](#respfig5){ref-type="fig"}). Consequently, we have removed the original note on vessel diameter and morphology from the revised manuscript. We also thank the reviewer for the comment on the ECM deposition. Indeed, it is impossible to judge if we face an increase of ECM in the GOF condition. We therefore have describe the vessels and the ECM in the revised manuscript as follows: "Although the vessel morphology did not show major differences regarding vessel perimeter and structure, the vessels of the GOF mice appeared to have a more compact ECM deposition in their circumference (Figure 7A-C)." (Results section). Together with the new Figure 7---figure supplement 2, showing the distribution of Lama2 and ColIV, we conclude that the ECM is not significantly affected by the induction of β-catenin signaling in ECs of the SFO.

> The data regards c-fos expression by neurons in the SFO are also an area where the conclusions do seem robust. Neuronal staining to show that this is neuronal and not glial localization is not there. Also, I some of the staining patterns are puzzling. Should not c-fos should look similar at 0h and isotonic NaCl panels in Figure 7, but they look hugely different, casting doubt over the quantifications in Figure 7E and F.

We thank the reviewer for this important comment. We agree that the c-fos staining of the 0 hour water restricted mice and the NaCl controls should be comparable, given that we identified nearly no c-fos staining in these control conditions, which the images of the original submission did not support well, due to some background staining in the 0 h panel in Figure 7C. Moreover, the neuronal identity of cell that show nuclear c-fos staining was missing in the originally submitted manuscript. Therefore, we have performed novel staining of samples from the water-restricted mice, combining the vascular marker CD31 with the neuron-specific Nissl staining and c-fos. The novel images of the new Figure 8C, D now show a comparable staining pattern between water restriction at 0 hour and the isotonic NaCl injected mice. Additionally, the Nissl staining of the so-called Nissl flounders nicely documents the neuronal identity of the c-fos^+^ cells (Figure 8G). As opposed to the general nuclear staining by the fluorescent Nissl stain, the flounders are specific for neurons only, that we indicated by the dashed lines in Figure 8G. The images show a high magnification of a Nissl^+^/c-fos^+^ double positive neuron in Figure 8G and a Nissl^+^/c-fos^-^ neuron in Figure 8H. We hope the pronounced differences in c-fos between the conditions are now comprehendible.

> The authors find increased expression of Sox17 along with Cldn5 in GOF experiments and note in conjunction with the TEM data that this may signify arterial specification. However, this is unfounded speculation in my opinion. There are many markers for arterial EC in the brain (see Vanlandewijck et al., 2018) and Sox17 is not a particularly strong one. The authors should remove this statement or investigate possible arterialization more thoroughly.

We thank the reviewer for this comment. The intention to show Sox17 was exclusively to demonstrate the upregulation of a Wnt/β-catenin target, and it was only a note that Sox17 was previously shown as an arterial marker. As suggested by the reviewer, we have deleted the statement of arterialisation, but described Sox17 solely as a Wnt target (Results section).

> The authors investigate Aqp4 and CD13 staining patterns to check \"other phenotypic BBB features\", but although neither Aqp4 nor CD13 was found changed in the GOF situation, it is unclear why the experiments were done in the first place. In what way do the (negative) data display an absence of BBB features? The meaning of the homogenous-looking Aqp4 staining in the CVOs is interesting but may have nothing to do with the absence of a BBB. Does the staining reflect lack of end-foot restricted localization in astrocytes, or is it the tanycytes that express Aqp4 in the CVOs? Also, what does the CD13-staining mean? Is this mural cells or perivascular fibroblasts (see Vanlandewijck et al., 2018)?

We thank the reviewer for making this comment. As mentioned above in context of the astrocytic end foot staining with α-dystroglycan (α-Dag), Kir4.1 and Lama2, we decided to keep and show also Aqp4. However, we clarified in the main text of the revised manuscript (Results section; Discussion section) that the intention to investigate Aqp4, and as suggested by the reviewers in addition α-Dag and Kir4.1, was to understand if the known lack of a BBB-like NVU organisation of astrocytes, pericytes and endothelial cells in the core of the SFO, was altered by β-catenin GOF in ECs. The combined findings from all markers stained suggest that dominant endothelial activation of β-catenin does not lead to a structural formation of an NVU in the core of the SFO. We believe that this is valuable information, opening new aspects of investigating cellular and molecular interactions at the NVU. Regarding the expression of Aqp4 in astrocytes or tanycytes, the novel data on Kir4.1 expression which likely resembles tanycytes and does not overlap with Aqp4, may suggest that Aqp4 is expressed in astrocytes. We agree with the reviewer that the data on pericytes were too preliminary and hence, we have removed these data from the revised manuscript. Just mentioning that we haven't seen obvious effects on this cell type as "data not shown", and that we haven't investigated perivascular fibroblasts identified by Vanlandewick et al., 2018 (Discussion section).
